Last reviewed · How we verify
GDC-0973 Oral Capsules
At a glance
| Generic name | GDC-0973 Oral Capsules |
|---|---|
| Also known as | XL518 |
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (PHASE2, PHASE3)
- Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (PHASE2)
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors (PHASE1)
- A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants (PHASE1)
- An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib) (PHASE1)
- Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation (PHASE1)
- Study of Cobimetinib in Participants With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GDC-0973 Oral Capsules CI brief — competitive landscape report
- GDC-0973 Oral Capsules updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI